2109730-69-8

2109730-69-8 structure

2109730-69-8 structure

Name: Benufutamab
Chemical Name: Benufutamab
CAS Number: 2109730-69-8
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-05-21 12:55:00
Modify Date: 2024-01-16 10:44:02
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects[1].

Name	Benufutamab

Description	Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects[1].
Related Catalog	Research Areas >> Cancer
In Vitro	Benufutamab（GEN1029；HexaBody-DR5/DR5；20 µg/mL；24 小时）在多发性骨髓瘤 (MM) 细胞中诱导强效细胞毒性[1]。 Cell Viability Assay[1] Cell Line: Multiple myeloma (MM) cells Concentration: 20 µg/mL Incubation Time: 24 hours Result: Induced potent cytotoxicity.
In Vivo	Benufutamab（GEN1029；HexaBody-DR5/DR5；0.5-2 mg/kg；腹腔注射；每周一次；持续 9 周）在结直肠癌的 PDX 模型中显示出显着的抗肿瘤活性[2]。 Animal Model: Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells[2] Dosage: 0.5 mg/kg, or 2 mg/kg Administration: i.p.; once a week; for 9 weeks Result: Showed significant antitumor activity.
References	[1]. Hilma J van der Horst, et al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2165-2172. [2]. Marije B Overdijk, et al. Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Mol Cancer Ther. 2020 Oct;19(10):2126-2138.

No Any Chemical & Physical Properties